N/A
Completed N=16,801
Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage
Triage · Risk Stratification With Biomarker
Source: ClinicalTrials.gov NCT02643459 ↗
Enrolled (actual)
16,801
Serious AEs
0.0%
Results posted
Mar 2021
Primary outcomePrimary: All Cause Mortality — 1126; 1241 Participants
Summary
Will clinical outcome for patients be improved if triage in Acute wards and Emergency rooms is supplemented with a prognostic biomarker?
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY All Cause Mortality |
319; 359 | — |
| SECONDARY All Cause Mortality |
319; 359 | — |
| SECONDARY Number of Discharges From the Emergency Room Within 24 Hours |
3934; 4352 | — |
| SECONDARY Number of Admissions to the Medical Ward |
3500; 3738 | — |
| SECONDARY Number of Patients With an Admission to the Intensive Care Unit |
1027; 1157 | — |
| SECONDARY Number of Patients With New Cancer Diagnosis in Control vs Intervention Groups |
687; 917 | — |
| SECONDARY Length of Stay During Admission. |
4.53; 4.39 | — |
| SECONDARY Number of Readmissions |
687; 917 | — |
Eligibility Criteria
Inclusion Criteria
- Patients presenting acutely to the Acute ward/Emergency department and have blood samples done which include both Hemoglobin, C reactive protein and Creatinine within 6 hours of registration within the study period. The study is carried out in 2 Hospitals in the Capital of Denmark.
Exclusion Criteria
- Patients presenting in Pediatric, Gynecological or Obstetric units. Patients not being examined with blood samples.
Data sourced from ClinicalTrials.gov (NCT02643459). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.